Yiwey Shieh, MD

Title(s)Affiliate, Surgery
SchoolSchool of Medicine
AddressLocation Required
ORCID ORCID Icon0000-0002-0159-7748 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard UniversityAB2006Biology
    University of California, San FranciscoMD2012School of Medicine
    Hospital of the University of PennsylvaniaResidency2015Internal Medicine - Primary Care
    University of California, San FranciscoMAS2017Clinical Research
    Collapse Awards and Honors
    UCSF Breast Oncology Program2017Best Poster, Epidemiology and Population Science
    Society of General Internal Medicine2017Finalist, Mack Lipkin Sr. Associate Member Scientific Presentation Award
    Society of General Internal Medicine2018Winner, Milton W. Hamolsky Junior Faculty Scientific Presentation Award

    Collapse Overview 
    Collapse Overview
    Yiwey Shieh, MD is an Assistant Professor in the Department of Medicine at the University of California, San Francisco (UCSF). Dr. Shieh is a general internist and clinical epidemiologist interested in improving the delivery of breast cancer screening and prevention through the use of risk stratification tools. His current work uses clinical risk factors, breast density, and genetic variants to refine individualized risk assessment, especially as it pertains to disease biology. As a clinician-investigator, he is particularly interested in how such tools can be used to improve clinical decision-making.

    Collapse Research 
    Collapse Research Activities and Funding
    Prediction of interval breast cancer risk using genetic variants
    NIH K08CA237829Jul 1, 2019 - Jun 30, 2024
    Role: Principal Investigator
    UCSF CTSI KL2 Career Development Award
    NIH/NCATS 1KL2TR001870Jun 1, 2018 - Jun 30, 2019
    Role: KL2 Scholar

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abstract 5883: Development and testing of a polygenic risk score for proliferative breast cancers. Cancer Research. 2022 Jun 15; 82(12_Supplement):5883-5883. Shieh SY, Roger RJ, Huntsman HS, Hu HD, Nierenberg NJ, Kapoor KP, Yau YC, Hirst HG, van 't Veer vL, Esserman EL. .
      View in: Publisher Site   Mentions:
    2. PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue. Biofactors. 2022 Sep; 48(5):1060-1075. Su SC, Chien CY, Chen YC, Chiang CF, Lin FH, Kuo FC, Huang CL, Li PF, Liu JS, Lu CH, Ho LJ, Hsieh CH, Hung YJ, Shieh YS, Lee CH. PMID: 35674710.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    3. Abstract P5-19-04: The WISDOM study: Reducing sequential steps and implementing parallel workflows in pragmatic trials. Cancer Research. 2022 Feb 15; 82(4_Supplement):p5-19-04-p5-19-04. Lewis LT, Flores FS, Sabacan SL, Choy CP, Thannickal TH, Shieh SY, Tice TJ, Ziv ZE, Madlensky ML, Eklund EM, Yau YC, Blanco BA, Tong TB, Goodman GD, Anderson AN, Harvey HH, Fors FS, Park PH, Raouf RS, Stewart SS, Wernisch WJ, Koenig KB, Kaplan KC, Hiatt HR, Wenger WN, Lee LV, Heditsian HD, Brain BS, Moorehead MD, Parker PB, Borowsky BA, Anton-Culver AH, Naeim NA, Kaster KA, van ‘t Veer vL, LaCroix LA, Olopade OO, Sheth SD, Garcia GA, Lancaster LR, Plaza PM, Fiscalini FA, Esserman EL. .
      View in: Publisher Site   Mentions:
    4. Abstract P5-19-01: The impact of streamlined processes and patient-directed messaging to improve enrollment in a remote, pragmatic clinical trial. Cancer Research. 2022 Feb 15; 82(4_Supplement):p5-19-01-p5-19-01. Choy CP, Lewis LT, Flores FS, Sabacan SL, Thannickal TH, Goodman GS, Shieh SY, Madlensky ML, Tice TJ, Ziv ZE, Eklund EM, Blanco BA, Tong TB, Goodman GD, Anderson AN, Harvey HH, Fors FS, Park PH, Petruse PA, Stewart SS, Raouf RS, Wernisch WJ, Koenig KB, Kaplan KC, Hiatt HR, Wenger WN, Lee LV, Heditsian HD, Brain BS, Moorehead MD, Parker PB, Borowsky BA, Anton-Culver AH, Naeim NA, Kaster KA, van 't Veer vL, LaCroix LA, Olopade OO, Sheth SD, Garcia GA, Lancaster LR, James JJ, Joseph JG, Study SW, Fiscallini FA, Esserman EL. .
      View in: Publisher Site   Mentions:
    5. Abstract PO-164: Pathogenic variants in breast cancer risk genes in Latinas. Cancer Epidemiology Biomarkers & Prevention. 2022 Jan 1; 31(1_Supplement):po-164-po-164. Nierenberg NJ, Adamson AA, Ding DY, Shieh SY, Hu HD, Huntsman HS, John JE, Torres-Mejia TG, Haiman HC, Kushi KL, Ricker RC, Steele SL, Lee LR, Weitzel WJ, Fejerman FL, Ziv ZE, Neuhausen NS. .
      View in: Publisher Site   Mentions:
    6. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast Cancer Res Treat. 2022 Feb; 191(3):623-629. Dreher N, Matthys M, Hadeler E, Shieh Y, Acerbi I, McAuley FM, Melisko M, Eklund M, Tice JA, Esserman LJ, Veer LJV. PMID: 34843026; PMCID: PMC9189918.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    7. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res Treat. 2021 Oct; 189(3):593-598. Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. PMID: 34529196.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    8. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. NPJ Breast Cancer. 2021 Aug 03; 7(1):102. Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ. PMID: 34344894; PMCID: PMC8333106.
      View in: PubMed   Mentions: 1  
    9. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. NPJ Breast Cancer. 2021 Jun 17; 7(1):78. Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ. PMID: 34140528; PMCID: PMC8211836.
      View in: PubMed   Mentions: 2  
    10. Abstract OT-21-01: Personalized breast cancer screening in a population-based study: Women informed to screen depending on measures of risk (WISDOM). Cancer Research. 2021 Feb 15; 81(4_Supplement):ot-21-01-ot-21-01. Acerbi AI, Fiscalini FA, Che CM, Shieh SY, Madlensky ML, Tice TJ, Ziv ZE, Eklund EM, Blanco BA, Tong TB, Goodman GD, Nassereddine NL, Anderson AN, Harvey HH, Fors FS, Park PH, Petruse PA, Stewart SS, Wernisch WJ, Risty RL, Hurley HI, Koenig KB, Kaplan KC, Hiatt HR, Wenger WN, Lee LV, Heditsian HD, Brain BS, Sabacan SL, Wang WT, Parker PB, Borowsky BA, Anton-Culver AH, Naeim NA, Kaster KA, Talley TM, van 't Veer vL, LaCroix LA, Olopade OO, Sheth SD, Garcia GA, Lancaster LR, Esserman EL. .
      View in: Publisher Site   Mentions:
    11. Medications for Primary Prevention of Breast Cancer. JAMA. 2020 07 21; 324(3):291-292. Shieh Y, Tice JA. PMID: 32692377; PMCID: PMC8216042.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    12. A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women. J Natl Cancer Inst. 2020 06 01; 112(6):590-598. Shieh Y, Fejerman L, Lott PC, Marker K, Sawyer SD, Hu D, Huntsman S, Torres J, Echeverry M, Bohórquez ME, Martínez-Chéquer JC, Polanco-Echeverry G, Estrada-Flórez AP, COLUMBUS Consortium, Haiman CA, John EM, Kushi LH, Torres-Mejía G, Vidaurre T, Weitzel JN, Zambrano SC, Carvajal-Carmona LG, Ziv E, Neuhausen SL. PMID: 31553449; PMCID: PMC7301155.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    13. Interval breast cancers - insights into a complex phenotype. Nat Rev Clin Oncol. 2020 03; 17(3):138-139. Shieh Y, Ziv E, Kerlikowske K. PMID: 31965086.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Abstract P2-10-05: A breast cancer multi-racial/ethnic polygenic risk score for improved personalized breast cancer screening. Cancer Research. 2020 Feb 15; 80(4_Supplement):p2-10-05-p2-10-05. Theiner TS, Hu HD, Huntsman HS, Shieh SY, Fejerman FL, Acerbi AI, Sawyer SS, Kendall KP, Zheng ZW, Huo HD, Olopade OO, Haiman HC, Kerlikowske KK, Cummings CS, John JE, Torres-Mejia TG, Kushi KL, Wolf WD, Tice TJ, Pearce PD, Esserman EL, van ‘t Veer vL, Ziv ZE. .
      View in: Publisher Site   Mentions:
    15. Abstract P5-08-01: Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network. Cancer Research. 2020 Feb 15; 80(4_Supplement):p5-08-01-p5-08-01. Huilgol HY, Keane KH, Shieh SY, Tice TJ, Ziv ZE, Madlensky ML, Sabacan SL, Acerbi AI, Che CM, Fiscalini FA, Anton-Culver AH, Borowsky BA, Hunt HS, Naeim NA, Parker PB, van 't Veer vL. .
      View in: Publisher Site   Mentions:
    16. Abstract P5-08-23: Personalized, prevention decision aid developed for breast cancer risk-reducing discussions and interventions in the WISDOM study. Cancer Research. 2020 Feb 15; 80(4_Supplement):p5-08-23-p5-08-23. Keane KH, Huilgol HY, Shibley SW, Shieh SY, Goodman GD, Tice TJ, Belkora BJ, Sepucha SK, Ozzane OE, Fiscalini FA, Esserman EL. .
      View in: Publisher Site   Mentions:
    17. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res. 2019 04 03; 21(1):48. Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, Brandt KR, Visscher DW, Shepherd JA, Tamimi RM, Vachon CM, Kerlikowske K. PMID: 30944014; PMCID: PMC6448282.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    18. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289. Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E. PMID: 30810870; PMCID: PMC8207533.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    19. A breast cancer risk model as a predictor of interval cancer rate and tumor characteristics. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):1506-1506. Dreher DN, Acerbi AI, Hadeler HE, Shieh SY, Melisko MM, Investigators and Advocates IA, Esserman EL, van 't Veer vL. .
      View in: Publisher Site   Mentions:
    20. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017; 3:34. Esserman LJ, WISDOM Study and Athena Investigators. PMID: 28944288; PMCID: PMC5597574.
      View in: PubMed   Mentions: 78  
    21. Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Res Treat. 2017 Nov; 166(2):603-612. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR. PMID: 28791495; PMCID: PMC5669824.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Low-Dose CT Scan for Lung Cancer Screening: Clinical and Coding Considerations. Chest. 2017 07; 152(1):204-209. Shieh Y, Bohnenkamp M. PMID: 28336485.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    23. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5). Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA, Athena Breast Health Network Investigators. PMID: 28130475.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    24. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016 Oct; 159(3):513-25. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E. PMID: 27565998; PMCID: PMC5033764.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    25. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016 09; 13(9):550-65. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. PMID: 27071351; PMCID: PMC6585415.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansPHPublic Health
    26. Detection of ductal carcinoma in situ and subsequent interval cancers. BMJ. 2016 Feb 01; 352:i551. Shieh Y, Eklund M, Esserman L. PMID: 26834245.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Ret?l VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. PMID: 21892702; PMCID: PMC5646368.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    28. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011 Aug; 129(1):165-73. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. PMID: 21390494.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansPHPublic Health
    29. Effect of screening on the detection of good and poor prognosis breast cancers. Journal of Clinical Oncology. 2010 May 20; 28(15_suppl):1520-1520. Shieh SY, Esserman EL, Rutgers RE, Knauer KM, Retel RV, Mook MS, Glas GA, Linn LS, van Leeuwen vF, van't Veer vL. .
      View in: Publisher Site   Mentions:
    30. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009 Oct 21; 302(15):1685-92. Esserman L, Shieh Y, Thompson I. PMID: 19843904.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansPHPublic Health
    31. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn. 2007 Sep; 7(5):533-44. Esserman LJ, Shieh Y, Park JW, Ozanne EM. PMID: 17892362.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Yiwey's Networks
    Concepts (99)
    Derived automatically from this person's publications.
    Co-Authors (25)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department